MTX and Steroid as First-line Therapy for aGVHD

Allo-HSCT is an effective treatment of malignant hematopoietic diseases. However, aGVHD remains a major complication after allo-HSCT and the destruction of recipient tissues by alloantigen-activated T cells is a key event in the development of aGVHD. Corticosteroid is the standard first-line therapy for aGVHD due to their roles in suppressing T cell responses. However, the response rate of corticosteroid was approximate 50%, and the clinical outcomes of patients with corticosteroid refractory GVHD were poor. Thus far, no combination therapy had been prove to be superior to corticosteroid alone as initial therapy for aGVHD. The study hypothesis: MTX combined corticosteroid treatment could help to further ameliorate the activity of T cells and control aGVHD.

Inclusion criteria

• Patients who are fully informed and sign informed consent by themselves or their guardians;
• Patients receiving allogeneic hematopoietic stem cell transplantation;
• Patients with acute graft-versus-host disease of grade II-IV were diagnosed after transplantation;
• Patients with stable implantation of granulocytes and platelets.
• ECOG score ≤3

Exclusion criteria

• Patients with severe brain, heart, kidney or liver dysfunction unrelated to graft-versus host disease;
• Patients with uncontrollable active infection;
• Patients with recurrence of primary malignant hematopathy;
• Expected survival is less than 3 months
• Patients who have histories of severe allergic reactions
• Pregnant or lactating women
• The researcher judges that there are other factors that are not suitable for participating